Ernexa Therapeutics Inc. Files 2024 Annual Proxy Statement
Ticker: ERNAW · Form: DEF 14A · Filed: Apr 14, 2025 · CIK: 748592
| Field | Detail |
|---|---|
| Company | Ernexa Therapeutics Inc. (ERNAW) |
| Form Type | DEF 14A |
| Filed Date | Apr 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, executive-compensation, corporate-governance
Related Tickers: ERNA
TL;DR
Ernexa (ERNA) proxy filed: details exec pay for Luther, Angel, Federoff for FY24. Governance insights.
AI Summary
Ernexa Therapeutics Inc. filed its DEF 14A on April 14, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board member information, including individuals like Mr. Luther, Dr. Angel, and Dr. Federoff, who served as members during the 2022, 2023, and 2024 fiscal years. The company, formerly known as Eterna Therapeutics Inc. and Brooklyn ImmunoTherapeutics, Inc., is based in Cambridge, MA.
Why It Matters
This filing provides crucial details on executive and director compensation, offering insight into how the company is rewarding its leadership and potentially influencing investor decisions regarding governance and pay practices.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and board information, which typically carries low risk unless specific unusual compensation packages or governance issues are highlighted.
Key Numbers
- 20241231 — Fiscal Year End (Reporting period for the proxy statement.)
- 20250414 — Filing Date (Date the DEF 14A was submitted to the SEC.)
Key Players & Entities
- Ernexa Therapeutics Inc. (company) — Filer
- Mr. Luther (person) — Board Member
- Dr. Angel (person) — Board Member
- Dr. Federoff (person) — Board Member
- Eterna Therapeutics Inc. (company) — Former Company Name
- Brooklyn ImmunoTherapeutics, Inc. (company) — Former Company Name
- NTN BUZZTIME INC (company) — Former Company Name
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide shareholders with information regarding the company's annual meeting, including details on executive compensation, board of directors, and corporate governance.
Who are the named board members mentioned in relation to compensation data?
The named board members mentioned in relation to compensation data for the fiscal years 2022, 2023, and 2024 include Mr. Luther, Dr. Angel, and Dr. Federoff.
What were Ernexa Therapeutics Inc.'s former names?
Ernexa Therapeutics Inc. was formerly known as Eterna Therapeutics Inc. (name change effective 20221017) and prior to that, Brooklyn ImmunoTherapeutics, Inc. (name change effective 20210325).
Where is Ernexa Therapeutics Inc. headquartered?
Ernexa Therapeutics Inc. is headquartered at 1035 Cambridge Street, Suite 18A, Cambridge, MA 02141.
What is the SIC code for Ernexa Therapeutics Inc.?
The Standard Industrial Classification (SIC) code for Ernexa Therapeutics Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 14, 2025 by Mr. Luther regarding Ernexa Therapeutics Inc. (ERNAW).